FDA authorizes Pfizer's booster shots for high-risk populations

The U.S. Food and Drug Administration agreed with a government advisory panel and approved the Pfizer-BioNTech COVID-19 vaccine booster for those who are 65 years and older or run a high risk of severe disease.